Literature DB >> 34623518

Molecular classification of hepatocellular carcinoma: prognostic importance and clinical applications.

Aroosha Raja1, Farhan Haq2.   

Abstract

Hepatocellular carcinoma (HCC) is a lethal human malignancy with a very low overall and long-term survival rate. Poor prognostic outcomes are predominantly associated with HCC due to a huge landscape of heterogeneity found in the deadliest disease. However, molecular subtyping of HCC has significantly improved the knowledge of the underlying mechanisms that contribute towards the heterogeneity and progression of the disease. In this review, we have extensively summarized the current information available about molecular classification of HCC. This review can be of great significance for providing the insight information needed for development of novel, efficient and personalized therapeutic options for the treatment of HCC patients globally.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  HCC; Molecular classification; Prognosis; Subtypes

Mesh:

Substances:

Year:  2021        PMID: 34623518     DOI: 10.1007/s00432-021-03826-w

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  114 in total

Review 1.  Met, metastasis, motility and more.

Authors:  Carmen Birchmeier; Walter Birchmeier; Ermanno Gherardi; George F Vande Woude
Journal:  Nat Rev Mol Cell Biol       Date:  2003-12       Impact factor: 94.444

2.  Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

Authors:  Derek Y Chiang; Augusto Villanueva; Yujin Hoshida; Judit Peix; Philippa Newell; Beatriz Minguez; Amanda C LeBlanc; Diana J Donovan; Swan N Thung; Manel Solé; Victoria Tovar; Clara Alsinet; Alex H Ramos; Jordi Barretina; Sasan Roayaie; Myron Schwartz; Samuel Waxman; Jordi Bruix; Vincenzo Mazzaferro; Azra H Ligon; Vesna Najfeld; Scott L Friedman; William R Sellers; Matthew Meyerson; Josep M Llovet
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

3.  Leukocyte cell-derived chemotaxin 2 antagonizes MET receptor activation to suppress hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B recruitment.

Authors:  Chi-Kuan Chen; Ching-Yao Yang; Kuo-Tai Hua; Kuo-Ti Hua; Ming-Chih Ho; Gunnar Johansson; Yung-Ming Jeng; Chiung-Nien Chen; Min-Wei Chen; Wei-Jiunn Lee; Jen-Liang Su; Tsung-Ching Lai; Chi-Chi Chou; Bing-Ching Ho; Chuan-Fa Chang; Po-Huang Lee; King-Jen Chang; Michael Hsiao; Ming-Tsan Lin; Min-Liang Kuo
Journal:  Hepatology       Date:  2014-01-16       Impact factor: 17.425

4.  Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.

Authors:  Julien Calderaro; Gabrielle Couchy; Sandrine Imbeaud; Giuliana Amaddeo; Eric Letouzé; Jean-Frédéric Blanc; Christophe Laurent; Yacine Hajji; Daniel Azoulay; Paulette Bioulac-Sage; Jean-Charles Nault; Jessica Zucman-Rossi
Journal:  J Hepatol       Date:  2017-05-19       Impact factor: 25.083

5.  Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification.

Authors:  Sung-Min Ahn; Se Jin Jang; Ju Hyun Shim; Deokhoon Kim; Seung-Mo Hong; Chang Ohk Sung; Daehyun Baek; Farhan Haq; Adnan Ahmad Ansari; Sun Young Lee; Sung-Min Chun; Seongmin Choi; Hyun-Jeung Choi; Jongkyu Kim; Sukjun Kim; Shin Hwang; Young-Joo Lee; Jong-Eun Lee; Wang-Rim Jung; Hye Yoon Jang; Eunho Yang; Wing-Kin Sung; Nikki P Lee; Mao Mao; Charles Lee; Jessica Zucman-Rossi; Eunsil Yu; Han Chu Lee; Gu Kong
Journal:  Hepatology       Date:  2014-09-22       Impact factor: 17.425

6.  Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment.

Authors:  Anuradha Budhu; Marshonna Forgues; Qing-Hai Ye; Hu-Liang Jia; Ping He; Krista A Zanetti; Udai S Kammula; Yidong Chen; Lun-Xiu Qin; Zhao-You Tang; Xin Wei Wang
Journal:  Cancer Cell       Date:  2006-08       Impact factor: 31.743

7.  Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression.

Authors:  Kai Breuhahn; Sebastian Vreden; Ramsi Haddad; Susanne Beckebaum; Dirk Stippel; Peer Flemming; Tanja Nussbaum; Wolfgang H Caselmann; Brian B Haab; Peter Schirmacher
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

8.  Identification of metastasis-related microRNAs in hepatocellular carcinoma.

Authors:  Anuradha Budhu; Hu-Liang Jia; Marshonna Forgues; Chang-Gong Liu; David Goldstein; Amy Lam; Krista A Zanetti; Qing-Hai Ye; Lun-Xiu Qin; Carlo M Croce; Zhao-You Tang; Xin Wei Wang
Journal:  Hepatology       Date:  2008-03       Impact factor: 17.425

Review 9.  Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma.

Authors:  Bin Chen; Lana Garmire; Diego F Calvisi; Mei-Sze Chua; Robin K Kelley; Xin Chen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-01-03       Impact factor: 46.802

10.  The clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma.

Authors:  Sung-Min Ahn; Farhan Haq; Inkeun Park; Jean-Charles Nault; Jessica Zucman-Rossi; Eunsil Yu
Journal:  BMC Cancer       Date:  2018-05-18       Impact factor: 4.430

View more
  3 in total

1.  Bioactive xanthones, benzophenones and biphenyls from mangosteen root with potential anti-migration against hepatocellular carcinoma cells.

Authors:  Siwattra Choodej; Kedkarn Koopklang; Achara Raksat; Natthaya Chuaypen; Khanitha Pudhom
Journal:  Sci Rep       Date:  2022-05-21       Impact factor: 4.996

2.  Liver-specific deletion of miR-181ab1 reduces liver tumour progression via upregulation of CBX7.

Authors:  Jinbiao Chen; Yang Zhao; Fan Zhang; Jia Li; Jade A Boland; Ngan Ching Cheng; Ken Liu; Jessamy C Tiffen; Patrick Bertolino; David G Bowen; Andreas Krueger; Leszek Lisowski; Ian E Alexander; Mathew A Vadas; Emad El-Omar; Jennifer R Gamble; Geoffrey W McCaughan
Journal:  Cell Mol Life Sci       Date:  2022-07-22       Impact factor: 9.207

3.  E2F1 as a potential prognostic and therapeutic biomarker by affecting tumor development and immune microenvironment in hepatocellular carcinoma.

Authors:  Zhibo Tan; Min Chen; Feng Peng; Pengfei Yang; Zhaoming Peng; Zhe Zhang; Xin Li; Xiaopeng Zhu; Lei Zhang; Yujie Zhao; Yajie Liu
Journal:  Transl Cancer Res       Date:  2022-08       Impact factor: 0.496

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.